<DOC>
	<DOCNO>NCT01641263</DOCNO>
	<brief_summary>The objective study evaluate ability behavioral intervention , cognitive behavioral therapy sleep quality ( CBT-SQ ) reduce sleep complaint , depression recurrence , cellular genomic marker inflammation old adult sleep complaint prior history depression . The investigator aim : 1 ) evaluate effect CBT-SQ vs. Sleep Seminar ( SS ) objective ( actigraphy ) subjective ( sleep diary ; questionnaire ) measure sleep symptom two-year follow-up ; 2 ) determine effect CBT-SQ vs. SS recurrence depressive symptom depression episode ( ) two-year follow-up . The investigator also secondarily examine effect CBT-SQ vs. SS cellular genomic marker inflammation two-year follow-up , explore whether marker inflammation cytokine gene explain variability risk depression recurrence old adult receive CBT-SQ vs. SS . The present study highly significant first study , investigator knowledge , focus prevention depression community dwell old adult history depression , target sleep disturbance , modifiable risk factor prevent depression recurrence .</brief_summary>
	<brief_title>Promoting Sleep Healthy Aging Research Study ( PRO-SHARE )</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Older adult &gt; = 60 year age Evidence selfreported sleep disturbance indexed PSQI score &gt; 5 . Psychiatric Disorders . 1. current major depressive disorder DSMIV psychiatric disorder ( e.g . substance dependence ) exception anxiety disorder ; 2. presence psychotic symptom 3. acute suicidal violent behavior history suicide attempt within last year ; Sleep Disorders . 4. current lifetime history sleep disorder ( sleep apnea , nocturnal myoclonus , phaseshift disorder ) identify SCIDIV Duke Structured Interview Sleep Disorders ( DSISD ) ; person comorbid insomnia include Medical condition . 5. severe acute medical illness ( e.g. , major surgery , metastatic cancer , stroke , myocardial infarction ) six month prior study entry presence comorbid medical condition ; 5 ) neurological disease ( e.g. , Parkinson 's disease , multiple sclerosis ; neurodegenerative dementia , ) ; 6. severe pain disorder require daily pain management ; 7. presence comorbid inflammatory disorder rheumatoid arthritis autoimmune disorder would confound assessment sleep well inflammatory marker ; 8. presence uncontrolled medical condition deem investigator interfere propose study procedure , put study participant undue risk ( e.g. , active heart failure categorize Class III great accord New York Heart Association criterion ; symptomatic cardiac arrhythmia ; symptomatic , hemodynamically significant mitral aortic valvular disease ) ; 9. presence chronic infection , may elevate proinflammatory cytokine . While exclude individual behavioral outcome measure subject . No analysis blood perform . ( If history acute infectious illness identify within two week schedule blood sampling , session reschedule occur outside two week period ) ; Medication substance use . 10. use hormone contain medication include steroid ; 11. immune modify drug target specific immune response agent TNF antagonist ; 12. daily use analgesic opioids . We include take psychotropic medication ( except antipsychotic medication treat depotneuroleptic within 6 month prior study entry ) In regard psychotropic medication use , quantify past , current , ongoing use psychotropic medication ( e.g. , selective serotonin reuptake inhibitor , antidepressant , anxiolytic , hypnotic , sedative ) ass effect medication primary outcome intervention , followup period .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Depression Prevention</keyword>
	<keyword>Sleep Disturbances</keyword>
	<keyword>Inflammatory Markers</keyword>
	<keyword>Treatments Sleep Problems</keyword>
</DOC>